About: Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Creator	Abbaspour Kasgari, Hamideh Alikhani, Ahmad Babamahmoodi, Farhang Davoudi Badabi, Ali Davoudi, Lotfollah Garratt, Anna Hedayatizadeh Omran, Akbar Hill, Andrew Levi, Jacob Merat, Shahin Moradi, Siavash Saeedi, Majid Shabani, Amir Simmons, Bryony Tirgar Fakheri, Hafez Wentzel, Hannah
Source	Medline; PMC
abstract	BACKGROUND: New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19. METHODS: This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1. RESULTS: Between 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6 days in both groups (P = 0.398). The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). There was no difference in the number of deaths between the groups (0 versus 3, P = 0.234). The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray’s P = 0.033). CONCLUSIONS: This randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1093/jac/dkaa332
bibo:pmid	32812025
has license	no-cc
schema:url	https://doi.org/10.1093/jac/dkaa332
resource representing a document's title	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
has PubMed Central identifier	PMC7454669
has PubMed identifier	32812025
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:PMC7454669#body_text
is schema:about of	named entity 'efficacy' named entity 'patients' named entity 'moderate' named entity 'IRCT' named entity 'SARS-CoV-2' named entity 'fever' named entity 'daclatasvir' named entity 'daclatasvir' named entity 'sofosbuvir/daclatasvir' named entity 'daclatasvir' named entity 'comorbidities' named entity 'sofosbuvir/daclatasvir' named entity 'antiviral' named entity 'A.M.S.' named entity 'RdRp' named entity 'Flaviviridae' named entity 'chloroquine' named entity 'Zika' named entity 'cumulative incidence' named entity 'R Foundation' named entity 'sofosbuvir' named entity 'ITT' named entity 'sofosbuvir/daclatasvir' named entity 'statistically significant' named entity 'multiorgan failure' named entity 'Sofosbuvir' named entity 'RNA viruses' named entity 'lopinavir/ritonavir' named entity 'hypertension' named entity 'daclatasvir' named entity 'Tehran' named entity 'China' named entity 'COVID-19' named entity 'COVID' named entity 'A.A.' named entity 'virus' named entity 'sofosbuvir/daclatasvir' named entity 'diabetes' named entity 'randomized trial' named entity 'clinical trial' named entity 'sofosbuvir' named entity 'positive-sense RNA' named entity 'invasive mechanical ventilation' named entity 'cellular death' named entity 'sofosbuvir' named entity 'cough' named entity 'phenytoin' named entity 'shortness of breath' named entity 'mechanical ventilation' named entity 'ribavirin' named entity 'cumulative incidence' named entity 'Iran' named entity 'renal insufficiency' named entity 'sofosbuvir' named entity 'sofosbuvir/daclatasvir' named entity 'control group' named entity 'Mazandaran Province' named entity 'COVID' named entity 'HCV' named entity 'STATA' named entity 'ribavirin' named entity 'Iran' named entity 'hypertension' named entity 'COVID' named entity 'SARS-CoV-2' named entity '3.6.3' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software